Penicillium Marneffei: A Pathogen on our Doorstep?

Supparatpinyo K. , Khamwan C. , Baosoung V. , Nelson K.E. , Sirisanthana T. Disseminated Penicillium marneffei infection in Southeast Asia. Lancet 1994; 344: 110–13

Ungpakorn R. Cutaneous manifestations of Penicillium marneffei infection. Curr Opin Inf Dis 2000; 13: 129–34

Sirisanthana T. Penicillium marneffei infection in patients with AIDS. Emerging Inf Dis 2001; 7(3 suppl): 561

Cooper C.R. Jr. , McGinnis M.R. Pathology of Penicillium marneffei. An emerging acquired immunodeficiency syndrome-related pathogen. Arch Pathol Lab Med 1997; 121: 798–804

Sirisanthana T. , Supparatpinyo K. , Perriens J. , Nelson K.E. Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 26: 1107–10

Supparatpinyo K. , Perriens J. , Nelson K.E. , Sirisanthana T. A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus. N Engl J Med 1998; 339: 1739–43

Supparatpinyo K. , Nelson K.E. , Merz W.G. . Response to anti-fungal therapy by human immunodeficiency virus-infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens. Antimicrob Agents Chemother 1993; 37: 2407–11

Chariyalertsak S. , Supparatpinyo K. , Sirisanthana T. , Nelson K.E. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin Inf Dis 2002; 34: 277–84